| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c593f5659ae047459aa84c0c690f7478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcc8cf5e45036f254921cc1b3721489a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d81ef167aeb7f39531d9f6aafa5ac125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2579198d8b486e77ed846c11dd2ac4de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d49c83facbca9b251906b3ebae18493
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a23eb069074806c79258d04a6d802bea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3015 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2011-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19a0c6b82246d0650efbd7b015800a11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98b97e2a90306294410ba3a95c72e1bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf2d5d1605ad4c2e21d112f1f16a0303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfe853b7098f5989a95a45e0444e8926
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d9923b8bd19968be13c69ec4aa65f86 |
| publicationDate |
2012-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012100573-A1 |
| titleOfInvention |
New molecular marker cuedc2 protein for prognostic determination of breast cancer endocrinology therapy |
| abstract |
Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrine drug therapy for the breast cancer patients and diagnosis of tumors such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrine drug therapy for the breast cancer patients and diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment. The new use of the CUEDC2 protein provides a new basis for determining a dosage regimen of adjuvant therapy after surgical operation of the breast cancer patients, thereby improving the therapeutic effect of the anti-cancer drugs and alleviating the suffering and economic burden of the patients. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113444802-A |
| priorityDate |
2011-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |